Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals
复制标题
DOI：
10.1016/s0140-6736(05)63014-0
复制
发表时间：
2005-05-21
期刊：
影响因子：
168.9
通讯作者：
Collins, R
中科院分区：
文献类型：
--
作者：
Mihaylova, B;Briggs, A;Collins, R
背景他汀类药物治疗可降低心脏病发作、中风和血运重建的发生率。方法将20536例40-80岁的血管疾病或糖尿病患者随机分为辛伐他汀组（10269例）和安慰剂组（10267例），分别给予辛伐他汀40 mg/d和安慰剂，平均治疗5年。比较了所有辛伐他汀组与所有安慰剂组受试者在预定治疗期间的住院和他汀类药物费用（2001年英国价格）。在不同类别的参与者中估计成本效益。结果辛伐他汀与22%（95%CI 16-27; p
Background Statin therapy reduces the rates of heart attack, stroke, and revascularisation among a wide range of individuals. Reliable assessment of its cost-effectiveness in different circumstances is needed.Methods 20 536 adults (aged 40-80 years) with vascular disease or diabetes were randomly allocated 40 mg sinnivastatin daily (10 269) or placebo (10 267) for an average of 5 years. Comparisons were made of hospitalisation and statin costs (2001 UK prices) during the scheduled treatment period between all simvastatin-allocated versus all placebo-allocated participants. Cost-effectiveness was estimated among different categories of participant.Findings Allocation to simvastatin was associated with a highly significant 22% (95% Cl 16-27; p